Report Overview

The EU Chronic Inflammatory Demyelinating Polyneuritis Market size stood at around USD xx billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period

Chronic inflammatory demyelinating polyneuropathy is a neurological disorder in which the body immune system attacks myelin which is an important part of the nervous system. It happens when the body immune system cannot differentiate between the bodys own cell and foreign cell and instead start destroying the healthy cells of the body. This can cause pain, impaired ability, loss of sensation, chronic fatigue and other problems, Different treatments can be used to treat this disease such as intravenous immunoglobulin, plasmapheresis, physiotherapy and others



Market Drivers

Increasing cases of autoimmune diseases will drive the growth of this marker. Rising awareness among population about CIPD will also accelerate the market growth. Increasing R&D associated with the plasma-derived medicines is also enhancing the market growth. Growing government support via awareness programs and drug approvals will also propel the market growth